Skip to main content
. 2024 Oct 15;14(10):4803–4816. doi: 10.62347/MWLI5585

Figure 2.

Figure 2

Comparison of expression levels of LCP1 and ADPGK in late-stage non-small cell lung cancer patients with KARS G12C mutation treated with PD-1 inhibitors. Note: LCP1: Leukocyte-specific protein 1; ADPGK: adenosine diphosphate-dependent glucokinase. *: P<0.05; **: P<0.01.